{"id":"https://openalex.org/W2159339248","doi":null,"title":"S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.","display_name":"S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.","publication_year":2000,"publication_date":"2000-01-01","ids":{"openalex":"https://openalex.org/W2159339248","mag":"2159339248","pmid":"https://pubmed.ncbi.nlm.nih.gov/10604931"},"language":"en","primary_location":{"id":"pmid:10604931","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10604931","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of pharmacology and experimental therapeutics","raw_type":"Comparative Study"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041494494","display_name":"Mark John Millan","orcid":"https://orcid.org/0000-0002-6253-0301","observed_orcids":["https://orcid.org/0000-0002-6253-0301"]},"institutions":[{"id":"https://openalex.org/I4405268767","display_name":"Institut de Recherches Internationales Servier (France)","ror":"https://ror.org/01zej3n42","country_code":"FR","type":"company","lineage":["https://openalex.org/I4405268767"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"M J Millan","raw_affiliation_strings":["Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, Paris, Croissy-sur-Seine, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, Paris, Croissy-sur-Seine, France","institution_ids":["https://openalex.org/I4405268767"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058418331","display_name":"Mauricette Brocco","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Brocco","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111535175","display_name":"Jean\u2010Michel Rivet","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J M Rivet","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007183018","display_name":"Val\u00e9rie Audinot","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V Audinot","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045801598","display_name":"Adrian Newman\u2010Tancredi","orcid":"https://orcid.org/0000-0002-2923-5714","observed_orcids":["https://orcid.org/0000-0002-2923-5714"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A Newman-Tancredi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001213943","display_name":"Lisa Maiofiss","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L Maiofiss","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062003040","display_name":"Sophie Queriaux","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S Queriaux","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048712019","display_name":"Nicole Despaux","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N Despaux","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110623308","display_name":"Jean-Louis P\u00e9glion","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J L Peglion","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5000682280","display_name":"Anne Dekeyne","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A Dekeyne","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":49,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"292","issue":"1","first_page":"54","last_page":"66"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9351000189781189,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9351000189781189,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.050700001418590546,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.003700000001117587,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.8289999961853027},{"id":"https://openalex.org/keywords/5-ht2a-receptor","display_name":"5-HT2A receptor","score":0.640999972820282},{"id":"https://openalex.org/keywords/dopamine-d1-receptor","display_name":"dopamine D1 receptor","score":0.5680000185966492},{"id":"https://openalex.org/keywords/dopamine-d2-receptor","display_name":"dopamine D2 receptor","score":0.6690000295639038},{"id":"https://openalex.org/keywords/nmda-receptor-antagonism","display_name":"NMDA receptor antagonism","score":0.6790000200271606},{"id":"https://openalex.org/keywords/clozapine","display_name":"clozapine","score":0.6179999709129333},{"id":"https://openalex.org/keywords/haloperidol","display_name":"haloperidol","score":0.996999979019165},{"id":"https://openalex.org/keywords/extrapyramidal-symptoms","display_name":"extrapyramidal symptoms","score":0.8259999752044678},{"id":"https://openalex.org/keywords/prolactin-secretion","display_name":"prolactin secretion","score":0.6850000023841858},{"id":"https://openalex.org/keywords/anxiolytic-effects","display_name":"anxiolytic effects","score":0.6940000057220459},{"id":"https://openalex.org/keywords/discriminative-stimuli","display_name":"discriminative stimulus","score":0.6119999885559082},{"id":"https://openalex.org/keywords/imidazolinones","display_name":"imidazolinones","score":0.5189999938011169},{"id":"https://openalex.org/keywords/piperidine","display_name":"piperidine","score":0.3720000088214874}],"concepts":[{"id":"https://openalex.org/C2779271588","wikidata":"https://www.wikidata.org/wiki/Q416414","display_name":"Tiapride","level":2,"score":0.6977185010910034},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.6898290514945984},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6894232034683228},{"id":"https://openalex.org/C2780864610","wikidata":"https://www.wikidata.org/wiki/Q221361","display_name":"Clozapine","level":3,"score":0.6632422208786011},{"id":"https://openalex.org/C2780948584","wikidata":"https://www.wikidata.org/wiki/Q251347","display_name":"Haloperidol","level":3,"score":0.6287485361099243},{"id":"https://openalex.org/C2780476085","wikidata":"https://www.wikidata.org/wiki/Q918193","display_name":"Catalepsy","level":4,"score":0.6077204346656799},{"id":"https://openalex.org/C2778851735","wikidata":"https://www.wikidata.org/wiki/Q407324","display_name":"Phencyclidine","level":4,"score":0.5562086701393127},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.44180119037628174},{"id":"https://openalex.org/C2777836312","wikidata":"https://www.wikidata.org/wiki/Q4386371","display_name":"Dizocilpine","level":4,"score":0.43679070472717285},{"id":"https://openalex.org/C2780616385","wikidata":"https://www.wikidata.org/wiki/Q1385411","display_name":"Extrapyramidal symptoms","level":4,"score":0.43211066722869873},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.3535090684890747},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3386612832546234},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.29079121351242065},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.24286964535713196},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.23839136958122253},{"id":"https://openalex.org/C67018056","wikidata":"https://www.wikidata.org/wiki/Q414896","display_name":"NMDA receptor","level":3,"score":0.2118208110332489},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.17353808879852295},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.09132033586502075},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.07930544018745422},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000374","descriptor_name":"Aggression","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D000661","descriptor_name":"Amphetamine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001058","descriptor_name":"Apomorphine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D001362","descriptor_name":"Avoidance Learning","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003024","descriptor_name":"Clozapine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D003042","descriptor_name":"Cocaine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005116","descriptor_name":"Extrapyramidal Tracts","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006220","descriptor_name":"Haloperidol","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007555","descriptor_name":"Isoxazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010147","descriptor_name":"Pain Measurement","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011485","descriptor_name":"Protein Binding","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011968","descriptor_name":"Receptors, Histamine","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D011976","descriptor_name":"Receptors, Muscarinic","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D017208","descriptor_name":"Rats, Wistar","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018492","descriptor_name":"Dopamine Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D018674","descriptor_name":"Adrenergic Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058668","descriptor_name":"Adrenergic alpha-1 Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058669","descriptor_name":"Adrenergic alpha-2 Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:10604931","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10604931","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of pharmacology and experimental therapeutics","raw_type":"Comparative Study"},{"id":"mag:2159339248","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10604931","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":55,"referenced_works":["https://openalex.org/W41829251","https://openalex.org/W1209980950","https://openalex.org/W1638544077","https://openalex.org/W1845737189","https://openalex.org/W1893531325","https://openalex.org/W1895729847","https://openalex.org/W1922093645","https://openalex.org/W1963484018","https://openalex.org/W1974070760","https://openalex.org/W1982539986","https://openalex.org/W1984733445","https://openalex.org/W1991370576","https://openalex.org/W1992156446","https://openalex.org/W1993683682","https://openalex.org/W1994219935","https://openalex.org/W1994921025","https://openalex.org/W1999901204","https://openalex.org/W2000627347","https://openalex.org/W2006749296","https://openalex.org/W2006767074","https://openalex.org/W2007220031","https://openalex.org/W2009798253","https://openalex.org/W2010596150","https://openalex.org/W2016381774","https://openalex.org/W2019233381","https://openalex.org/W2027610146","https://openalex.org/W2027782078","https://openalex.org/W2032371154","https://openalex.org/W2034967655","https://openalex.org/W2036534852","https://openalex.org/W2037833537","https://openalex.org/W2039800019","https://openalex.org/W2054789315","https://openalex.org/W2059189197","https://openalex.org/W2060341999","https://openalex.org/W2068147087","https://openalex.org/W2070605348","https://openalex.org/W2072697155","https://openalex.org/W2077149536","https://openalex.org/W2080610590","https://openalex.org/W2082412690","https://openalex.org/W2083252023","https://openalex.org/W2084768065","https://openalex.org/W2086687352","https://openalex.org/W2090415417","https://openalex.org/W2093305907","https://openalex.org/W2094417837","https://openalex.org/W2096824787","https://openalex.org/W2123268199","https://openalex.org/W2167381827","https://openalex.org/W2168836105","https://openalex.org/W2187524630","https://openalex.org/W2213544100","https://openalex.org/W2270567474","https://openalex.org/W2796737170"],"related_works":["https://openalex.org/W4406056443","https://openalex.org/W1921195162","https://openalex.org/W7098193052","https://openalex.org/W4406056441","https://openalex.org/W2169664320","https://openalex.org/W1845737189","https://openalex.org/W2313653727","https://openalex.org/W2006729014","https://openalex.org/W2008825026","https://openalex.org/W2084253035"],"abstract_inverted_index":{"S18327":[0,42,58,106,115,157,181,197,213,235],"was":[1],"dose-dependently":[2],"active":[3,159],"in":[4,18,25,32,51,85,126,130,137,144,160,179],"several":[5],"models":[6,54,161],"of":[7,15,20,28,55,72,91,156,163,169,176,193,218],"potential":[8,164,219],"antipsychotic":[9,220],"activity":[10,221],"involving":[11],"dopaminergic":[12],"hyperactivity:":[13],"inhibition":[14,125,175],"apomorphine-induced":[16],"climbing":[17],"mice,":[19,132],"cocaine-":[21],"and":[22,27,47,61,94,101,122,133,141,171,174,188,204,208,244,250],"amphetamine-induced":[23],"hyperlocomotion":[24,60],"rats,":[26,127],"conditioned":[29],"avoidance":[30],"responses":[31],"rats.":[33,52,145,180],"Furthermore,":[34],"reflecting":[35],"its":[36,76],"high":[37],"affinity":[38,185,247],"at":[39,79,222],"serotonin(2A)":[40],"sites,":[41],"potently":[43],"blocked":[44,59,128],"phencyclidine-induced":[45],"locomotion":[46],"1-[2,":[48],"5-dimethoxy-4-iodophenyl]-2-aminopropane-induced":[49],"head-twitches":[50],"In":[53,211,232],"glutamatergic":[56],"hypoactivity,":[57],"spontaneous":[62],"tail-flicks":[63],"elicited":[64],"by":[65,98],"the":[66,102,138,148],"N-methyl-D-aspartate":[67],"antagonist":[68],"dizocilpine.":[69],"The":[70],"actions":[71],"S18327,":[73],"together":[74],"with":[75,89,111],"binding":[77],"profile":[78],"multiple":[80],"monoaminergic":[81],"receptors":[82],"(15":[83],"parameters":[84],"total),":[86],"were":[87,158],"compared":[88],"those":[90,227],"clozapine,":[92,238],"haloperidol,":[93],"11":[95],"other":[96],"antipsychotics":[97],"multiparametric":[99],"analysis,":[100],"resulting":[103],"dendrogram":[104],"positioned":[105],"close":[107],"to":[108,117,147],"clozapine.":[109],"Consistent":[110],"a":[112,118,215],"clopazine-like":[113],"profile,":[114],"generalized":[116],"clozapine":[119,205],"discriminative":[120],"stimulus":[121],"evoked":[123],"latent":[124],"aggression":[129],"isolated":[131],"displayed":[134],"anxiolytic":[135],"properties":[136],"ultrasonic":[139],"vocalization":[140],"Vogel":[142],"procedures":[143],"Relative":[146],"above":[149],"paradigms,":[150],"only":[151,183],"markedly":[152],"(>20-fold)":[153],"higher":[154],"doses":[155,223],"predictive":[162],"extrapyramidal":[165,202,229],"side":[166,230],"effects:":[167],"induction":[168],"catalepsy":[170],"prolactin":[172],"secretion,":[173],"methylphenidate-induced":[177],"gnawing":[178],"showed":[182],"modest":[184],"for":[186,248],"histaminic":[187,207,249],"muscarinic":[189,209,251],"receptors.":[190,252],"Multiparametric":[191],"analysis":[192],"these":[194],"data":[195],"distinguished":[196],"from":[198],"both":[199],"haloperidol":[200],"(high":[201,206],"potential)":[203],"affinity).":[210],"conclusion,":[212],"displays":[214,245],"broad-based":[216],"pattern":[217],"appreciably":[224],"lower":[225],"than":[226],"eliciting":[228],"effects.":[231],"this":[233],"respect,":[234],"closely":[236],"resembles":[237],"but":[239],"it":[240],"is":[241],"chemically":[242],"distinct":[243],"weak":[246]},"counts_by_year":[{"year":2022,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":3},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}